undamentalytics Newsletter
Sign in

Janux Therapeutics, Inc. revenue

Janux Therapeutics, Inc.'s revenue was $10.0m in fiscal 2025, down 5.6% on the year before. Since fiscal 2021 ($3.6m) it has grown at a compound 28.8% a year. Over the last twelve months it was $24.0m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0498111024
Growth on the year before——+136.8%−6.1%+31.0%−5.6%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Janux Therapeutics, Inc. $24.0m 5367.0% 45.7%
Crispr Therapeutics AG $25.2m -34.3% -47.1%
Abeona Therapeutics Inc. $25.5m -87.7% 212.0%
Stoke Therapeutics, Inc. $27.6m -86.2% 46.1%
Monte Rosa Therapeutics, Inc. $28.7m -83.9% —
Tonix Pharmaceuticals Holding Corp. $29.1m 196.0% —

Compare with peers

Head to head: CRSP vs JANXABEO vs JANXJANX vs STOK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Janux Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Janux Therapeutics, Inc.